Click here to get full coverage on Why (ARVN) Price Action Is Critical for Tactical Trading - Stock Traders Daily

Why (ARVN) Price Action Is Critical for Tactical Trading  Stock Traders Daily

Why (ARVN) Price Action Is Critical for Tactical Trading - Stock Traders Daily

Click here to get full coverage on Arvinas (ARVN) moves 6.9% higher: Will this strength last? - MSN

Arvinas (ARVN) moves 6.9% higher: Will this strength last?  MSN

Arvinas (ARVN) moves 6.9% higher: Will this strength last? - MSN

Click here to get full coverage on How The Arvinas (ARVN) Story Is Evolving As 2026 Neurology Catalysts Approach - Yahoo Finance

How The Arvinas (ARVN) Story Is Evolving As 2026 Neurology Catalysts Approach  Yahoo Finance

How The Arvinas (ARVN) Story Is Evolving As 2026 Neurology Catalysts Approach - Yahoo Finance

Click here to get full coverage on JPMorgan Chase & Co. Has $1.83 Million Stock Holdings in Arvinas, Inc. $ARVN - MarketBeat

JPMorgan Chase & Co. Has $1.83 Million Stock Holdings in Arvinas, Inc. $ARVN  MarketBeat

JPMorgan Chase & Co. Has $1.83 Million Stock Holdings in Arvinas, Inc. $ARVN - MarketBeat

Click here to get full coverage on Experimental Parkinson’s pill from Arvinas cuts key brain protein by 50% - Stock Titan

Experimental Parkinson’s pill from Arvinas cuts key brain protein by 50%  Stock Titan

Experimental Parkinson’s pill from Arvinas cuts key brain protein by 50% - Stock Titan

Click here to get full coverage on $ARVN stock is down 8% today. Here's what we see in our data. - Quiver Quantitative

$ARVN stock is down 8% today. Here's what we see in our data.  Quiver Quantitative

$ARVN stock is down 8% today. Here's what we see in our data. - Quiver Quantitative

Click here to get full coverage on A Quick Look at Today's Ratings for Arvinas(ARVN.US), With a Forecast Between $11 to $21 - 富途牛牛

A Quick Look at Today's Ratings for Arvinas(ARVN.US), With a Forecast Between $11 to $21  富途牛牛

A Quick Look at Today's Ratings for Arvinas(ARVN.US), With a Forecast Between $11 to $21 - 富途牛牛

Click here to get full coverage on ARVN Stock Drops On CEO Exit — Retail Is Bullish On New Chief’s Credentials, Dismisses Selloff - Stocktwits

ARVN Stock Drops On CEO Exit — Retail Is Bullish On New Chief’s Credentials, Dismisses Selloff  Stocktwits

ARVN Stock Drops On CEO Exit — Retail Is Bullish On New Chief’s Credentials, Dismisses Selloff - Stocktwits

Click here to get full coverage on ARVN Technical Analysis & Stock Price Forecast - Intellectia AI

ARVN Technical Analysis & Stock Price Forecast  Intellectia AI

ARVN Technical Analysis & Stock Price Forecast - Intellectia AI

Click here to get full coverage on ARVINAS ($ARVN) Releases Q4 2025 Earnings - Quiver Quantitative

ARVINAS ($ARVN) Releases Q4 2025 Earnings  Quiver Quantitative

ARVINAS ($ARVN) Releases Q4 2025 Earnings - Quiver Quantitative

Click here to get full coverage on Here's Why We're Not Too Worried About Arvinas' (NASDAQ:ARVN) Cash Burn Situation - Yahoo Finance

Here's Why We're Not Too Worried About Arvinas' (NASDAQ:ARVN) Cash Burn Situation  Yahoo Finance

Here's Why We're Not Too Worried About Arvinas' (NASDAQ:ARVN) Cash Burn Situation - Yahoo Finance

Click here to get full coverage on Arvinas (NASDAQ:ARVN) Shares Down 5.1% - Time to Sell? - MarketBeat

Arvinas (NASDAQ:ARVN) Shares Down 5.1% - Time to Sell?  MarketBeat

Arvinas (NASDAQ:ARVN) Shares Down 5.1% - Time to Sell? - MarketBeat

Click here to get full coverage on Vanguard realignment leaves Arvinas (ARVN) ownership listed as 0 shares - Stock Titan

Vanguard realignment leaves Arvinas (ARVN) ownership listed as 0 shares  Stock Titan

Vanguard realignment leaves Arvinas (ARVN) ownership listed as 0 shares - Stock Titan

Click here to get full coverage on $ARVN stock is up 14% today. Here's what we see in our data. - Quiver Quantitative

$ARVN stock is up 14% today. Here's what we see in our data.  Quiver Quantitative

$ARVN stock is up 14% today. Here's what we see in our data. - Quiver Quantitative

Click here to get full coverage on Arvinas (ARVN) price target increased by 13.60% to 15.54 - MSN

Arvinas (ARVN) price target increased by 13.60% to 15.54  MSN

Arvinas (ARVN) price target increased by 13.60% to 15.54 - MSN

Click here to get full coverage on Arvinas, Inc. (ARVN) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Finance

Arvinas, Inc. (ARVN) Reports Q4 Loss, Misses Revenue Estimates  Yahoo Finance

Arvinas, Inc. (ARVN) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Finance

Click here to get full coverage on ARVN Oct 2026 12.000 put (ARVN261016P00012000) interactive stock chart - Yahoo Finance Singapore

ARVN Oct 2026 12.000 put (ARVN261016P00012000) interactive stock chart  Yahoo Finance Singapore

ARVN Oct 2026 12.000 put (ARVN261016P00012000) interactive stock chart - Yahoo Finance Singapore

Click here to get full coverage on How The Arvinas (ARVN) Narrative Is Evolving With New Leadership And Key 2026 Pipeline Catalysts - Yahoo Finance

How The Arvinas (ARVN) Narrative Is Evolving With New Leadership And Key 2026 Pipeline Catalysts  Yahoo Finance

How The Arvinas (ARVN) Narrative Is Evolving With New Leadership And Key 2026 Pipeline Catalysts - Yahoo Finance

Click here to get full coverage on Arvinas (ARVN) Rises 6.9%: Can This Momentum Be Sustained? - Bitget

Arvinas (ARVN) Rises 6.9%: Can This Momentum Be Sustained?  Bitget

Arvinas (ARVN) Rises 6.9%: Can This Momentum Be Sustained? - Bitget

Click here to get full coverage on ARVN Jul 2026 7.000 put (ARVN260717P00007000) Stock Historical Prices & Data - Yahoo! Finance Canada

ARVN Jul 2026 7.000 put (ARVN260717P00007000) Stock Historical Prices & Data  Yahoo! Finance Canada

ARVN Jul 2026 7.000 put (ARVN260717P00007000) Stock Historical Prices & Data - Yahoo! Finance Canada

Click here to get full coverage on Biotech behind first PROTAC trial taps dealmaker Randy Teel as CEO - Stock Titan

Biotech behind first PROTAC trial taps dealmaker Randy Teel as CEO  Stock Titan

Biotech behind first PROTAC trial taps dealmaker Randy Teel as CEO - Stock Titan

Click here to get full coverage on Arvinas (ARVN) CMO reports automatic RSU tax-withholding share sale - Stock Titan

Arvinas (ARVN) CMO reports automatic RSU tax-withholding share sale  Stock Titan

Arvinas (ARVN) CMO reports automatic RSU tax-withholding share sale - Stock Titan

Click here to get full coverage on Arvinas (ARVN) settles 6,022 RSUs; insider sold 5,685 shares - Stock Titan

Arvinas (ARVN) settles 6,022 RSUs; insider sold 5,685 shares  Stock Titan

Arvinas (ARVN) settles 6,022 RSUs; insider sold 5,685 shares - Stock Titan

Click here to get full coverage on Early ARV-102 Parkinson’s data to debut at Alzheimer’s-Parkinson’s conference - Stock Titan

Early ARV-102 Parkinson’s data to debut at Alzheimer’s-Parkinson’s conference  Stock Titan

Early ARV-102 Parkinson’s data to debut at Alzheimer’s-Parkinson’s conference - Stock Titan

Click here to get full coverage on Arvinas, Inc. (ARVN) Makes Significant Progress on Oncology and Neurology Trials - Yahoo Finance

Arvinas, Inc. (ARVN) Makes Significant Progress on Oncology and Neurology Trials  Yahoo Finance

Arvinas, Inc. (ARVN) Makes Significant Progress on Oncology and Neurology Trials - Yahoo Finance

Click here to get full coverage on ARVN Jan 2028 10.000 put (ARVN280121P00010000) interactive stock chart - Yahoo Finance Singapore

ARVN Jan 2028 10.000 put (ARVN280121P00010000) interactive stock chart  Yahoo Finance Singapore

ARVN Jan 2028 10.000 put (ARVN280121P00010000) interactive stock chart - Yahoo Finance Singapore

Click here to get full coverage on Ngo Quang Truong South Vietnam ARVN - HistoryNet

Ngo Quang Truong South Vietnam ARVN  HistoryNet

Ngo Quang Truong South Vietnam ARVN - HistoryNet

Click here to get full coverage on Arvinas (NASDAQ:ARVN) Shares Down 7.8% - What's Next? - MarketBeat

Arvinas (NASDAQ:ARVN) Shares Down 7.8% - What's Next?  MarketBeat

Arvinas (NASDAQ:ARVN) Shares Down 7.8% - What's Next? - MarketBeat

Click here to get full coverage on Wall Street Analysts Think Arvinas (ARVN) Could Surge 25.57%: Read This Before Placing a Bet - Yahoo Finance

Wall Street Analysts Think Arvinas (ARVN) Could Surge 25.57%: Read This Before Placing a Bet  Yahoo Finance

Wall Street Analysts Think Arvinas (ARVN) Could Surge 25.57%: Read This Before Placing a Bet - Yahoo Finance

Click here to get full coverage on Arvinas cuts costs, holds $685M ahead of June FDA breast cancer ruling - Stock Titan

Arvinas cuts costs, holds $685M ahead of June FDA breast cancer ruling  Stock Titan

Arvinas cuts costs, holds $685M ahead of June FDA breast cancer ruling - Stock Titan

Click here to get full coverage on Earnings To Watch: Arvinas Inc (ARVN) Reports Q3 2025 Result - Yahoo Finance

Earnings To Watch: Arvinas Inc (ARVN) Reports Q3 2025 Result  Yahoo Finance

Earnings To Watch: Arvinas Inc (ARVN) Reports Q3 2025 Result - Yahoo Finance

Click here to get full coverage on ARVN Oct 2026 15.000 call (ARVN261016C00015000) stock price, news, quote and history - Yahoo Finance Singapore

ARVN Oct 2026 15.000 call (ARVN261016C00015000) stock price, news, quote and history  Yahoo Finance Singapore

ARVN Oct 2026 15.000 call (ARVN261016C00015000) stock price, news, quote and history - Yahoo Finance Singapore

Click here to get full coverage on ARVN Apr 2026 10.000 put (ARVN260417P00010000) Interactive Stock Chart - Yahoo! Finance Canada

ARVN Apr 2026 10.000 put (ARVN260417P00010000) Interactive Stock Chart  Yahoo! Finance Canada

ARVN Apr 2026 10.000 put (ARVN260417P00010000) Interactive Stock Chart - Yahoo! Finance Canada

Click here to get full coverage on ARVN Jan 2027 7.000 call (ARVN270115C00007000) stock historical prices and data - Yahoo Finance Singapore

ARVN Jan 2027 7.000 call (ARVN270115C00007000) stock historical prices and data  Yahoo Finance Singapore

ARVN Jan 2027 7.000 call (ARVN270115C00007000) stock historical prices and data - Yahoo Finance Singapore

Click here to get full coverage on ARVN: Evercore ISI Raises Price Target to $19, Maintains Outperf - GuruFocus

ARVN: Evercore ISI Raises Price Target to $19, Maintains Outperf  GuruFocus

ARVN: Evercore ISI Raises Price Target to $19, Maintains Outperf - GuruFocus

Click here to get full coverage on ARVN May 2026 9.000 put (ARVN260515P00009000) stock historical prices and data - Yahoo Finance Singapore

ARVN May 2026 9.000 put (ARVN260515P00009000) stock historical prices and data  Yahoo Finance Singapore

ARVN May 2026 9.000 put (ARVN260515P00009000) stock historical prices and data - Yahoo Finance Singapore

Click here to get full coverage on Arvinas (ARVN): Losses Accelerate 7.7% Annually, but Stock Trades at Peer-Low 1.9x Sales - Yahoo Finance

Arvinas (ARVN): Losses Accelerate 7.7% Annually, but Stock Trades at Peer-Low 1.9x Sales  Yahoo Finance

Arvinas (ARVN): Losses Accelerate 7.7% Annually, but Stock Trades at Peer-Low 1.9x Sales - Yahoo Finance

Click here to get full coverage on Analysts Offer Insights on Healthcare Companies: Arvinas Holding Company (ARVN), HOYA (OtherHOCPF) and TransMedics Group (TMDX) - The Globe and Mail

Analysts Offer Insights on Healthcare Companies: Arvinas Holding Company (ARVN), HOYA (OtherHOCPF) and TransMedics Group (TMDX)  The Globe and Mail

Analysts Offer Insights on Healthcare Companies: Arvinas Holding Company (ARVN), HOYA (OtherHOCPF) and TransMedics Group (TMDX) - The Globe and Mail

Click here to get full coverage on Arvinas (ARVN) reports positive Phase 1 ARV-102 data in Parkinson’s disease - Stock Titan

Arvinas (ARVN) reports positive Phase 1 ARV-102 data in Parkinson’s disease  Stock Titan

Arvinas (ARVN) reports positive Phase 1 ARV-102 data in Parkinson’s disease - Stock Titan

Click here to get full coverage on Arvinas (ARVN) corrects CEO equity grant to 147,179 RSUs in Form 4/A - Stock Titan

Arvinas (ARVN) corrects CEO equity grant to 147,179 RSUs in Form 4/A  Stock Titan

Arvinas (ARVN) corrects CEO equity grant to 147,179 RSUs in Form 4/A - Stock Titan

Click here to get full coverage on Insider List - GuruFocus

Insider List - GuruFocus

Click here to get full coverage on $100M Cost Savings: Arvinas Restructures, Out-Licenses Cancer Drug & Launches Major Share Buyback - Stock Titan

$100M Cost Savings: Arvinas Restructures, Out-Licenses Cancer Drug & Launches Major Share Buyback  Stock Titan

$100M Cost Savings: Arvinas Restructures, Out-Licenses Cancer Drug & Launches Major Share Buyback - Stock Titan

Click here to get full coverage on Arvinas (NASDAQ:ARVN) Stock Price Expected to Rise, BTIG Research Analyst Says - MarketBeat

Arvinas (NASDAQ:ARVN) Stock Price Expected to Rise, BTIG Research Analyst Says  MarketBeat

Arvinas (NASDAQ:ARVN) Stock Price Expected to Rise, BTIG Research Analyst Says - MarketBeat

Click here to get full coverage on Arvinas (ARVN) Set to Announce Q4 Earnings Amid Mixed Expectatio - GuruFocus

Arvinas (ARVN) Set to Announce Q4 Earnings Amid Mixed Expectatio  GuruFocus

Arvinas (ARVN) Set to Announce Q4 Earnings Amid Mixed Expectatio - GuruFocus

Click here to get full coverage on Arvinas, Inc. (NASDAQ:ARVN) Receives Average Rating of "Hold" from Analysts - MarketBeat

Arvinas, Inc. (NASDAQ:ARVN) Receives Average Rating of "Hold" from Analysts  MarketBeat

Arvinas, Inc. (NASDAQ:ARVN) Receives Average Rating of "Hold" from Analysts - MarketBeat

Click here to get full coverage on Arvinas Inc (ARVN) Q3 2025 Earnings Call Highlights: Clinical Advancements and Strategic ... - Yahoo Finance

Arvinas Inc (ARVN) Q3 2025 Earnings Call Highlights: Clinical Advancements and Strategic ...  Yahoo Finance

Arvinas Inc (ARVN) Q3 2025 Earnings Call Highlights: Clinical Advancements and Strategic ... - Yahoo Finance

Click here to get full coverage on Noah Berkowitz Sells 6,435 Shares of Arvinas (NASDAQ:ARVN) Stock - MarketBeat

Noah Berkowitz Sells 6,435 Shares of Arvinas (NASDAQ:ARVN) Stock  MarketBeat

Noah Berkowitz Sells 6,435 Shares of Arvinas (NASDAQ:ARVN) Stock - MarketBeat

Click here to get full coverage on Is Arvinas Stock Built to Withstand More Downside? - Trefis

Is Arvinas Stock Built to Withstand More Downside?  Trefis

Is Arvinas Stock Built to Withstand More Downside? - Trefis

Click here to get full coverage on Arvinas (ARVN) Appoints New CEO as Leadership Changes Unfold - GuruFocus

Arvinas (ARVN) Appoints New CEO as Leadership Changes Unfold  GuruFocus

Arvinas (ARVN) Appoints New CEO as Leadership Changes Unfold - GuruFocus

Click here to get full coverage on Arvinas, Inc. to Participate in Four Upcoming Investor Conferences in March 2026 - Quiver Quantitative

Arvinas, Inc. to Participate in Four Upcoming Investor Conferences in March 2026  Quiver Quantitative

Arvinas, Inc. to Participate in Four Upcoming Investor Conferences in March 2026 - Quiver Quantitative

Click here to get full coverage on Possible Bearish Signals With Arvinas Insiders Disposing Stock - simplywall.st

Possible Bearish Signals With Arvinas Insiders Disposing Stock  simplywall.st

Possible Bearish Signals With Arvinas Insiders Disposing Stock - simplywall.st

Click here to get full coverage on Arvinas (ARVN) Reports Significant Revenue Decline and Sets Ambi - GuruFocus

Arvinas (ARVN) Reports Significant Revenue Decline and Sets Ambi  GuruFocus

Arvinas (ARVN) Reports Significant Revenue Decline and Sets Ambi - GuruFocus

Click here to get full coverage on Arvinas (ARVN) Projects Financial Stability into Late 2028 - GuruFocus

Arvinas (ARVN) Projects Financial Stability into Late 2028  GuruFocus

Arvinas (ARVN) Projects Financial Stability into Late 2028 - GuruFocus

Click here to get full coverage on ARVN Stock: Citigroup Upgrades Arvinas to 'Buy' with 50% Target - GuruFocus

ARVN Stock: Citigroup Upgrades Arvinas to 'Buy' with 50% Target  GuruFocus

ARVN Stock: Citigroup Upgrades Arvinas to 'Buy' with 50% Target - GuruFocus

Click here to get full coverage on Arvinas Stock Pre-Market (+4.7%): Broad Biotech Rally on Geopolitical De-escalation, Falling Oil - Trefis

Arvinas Stock Pre-Market (+4.7%): Broad Biotech Rally on Geopolitical De-escalation, Falling Oil  Trefis

Arvinas Stock Pre-Market (+4.7%): Broad Biotech Rally on Geopolitical De-escalation, Falling Oil - Trefis

Click here to get full coverage on Investors in Arvinas (NASDAQ:ARVN) have unfortunately lost 86% over the last three years - Yahoo Finance

Investors in Arvinas (NASDAQ:ARVN) have unfortunately lost 86% over the last three years  Yahoo Finance

Investors in Arvinas (NASDAQ:ARVN) have unfortunately lost 86% over the last three years - Yahoo Finance

Click here to get full coverage on Earnings Breakdown: Arvinas Q4 - Benzinga

Earnings Breakdown: Arvinas Q4  Benzinga

Earnings Breakdown: Arvinas Q4 - Benzinga

Click here to get full coverage on Arvinas’ (ARVN) chief medical officer Berkowitz sells $67,594 in stock - Investing.com

Arvinas’ (ARVN) chief medical officer Berkowitz sells $67,594 in stock  Investing.com

Arvinas’ (ARVN) chief medical officer Berkowitz sells $67,594 in stock - Investing.com

Click here to get full coverage on Arvinas: A Potential 'Sum Of The Parts' Story (NASDAQ:ARVN) - Seeking Alpha

Arvinas: A Potential 'Sum Of The Parts' Story (NASDAQ:ARVN)  Seeking Alpha

Arvinas: A Potential 'Sum Of The Parts' Story (NASDAQ:ARVN) - Seeking Alpha

Click here to get full coverage on Citigroup Raises Price Target for Arvinas (ARVN) to $18.00 | ARV - GuruFocus

Citigroup Raises Price Target for Arvinas (ARVN) to $18.00 | ARV  GuruFocus

Citigroup Raises Price Target for Arvinas (ARVN) to $18.00 | ARV - GuruFocus

Click here to get full coverage on Arvinas (ARVN): Wedbush Maintains Neutral Rating and Raises Pric - GuruFocus

Arvinas (ARVN): Wedbush Maintains Neutral Rating and Raises Pric  GuruFocus

Arvinas (ARVN): Wedbush Maintains Neutral Rating and Raises Pric - GuruFocus

Click here to get full coverage on ARVN veterans to be honored - orange county tribune

ARVN veterans to be honored  orange county tribune

ARVN veterans to be honored - orange county tribune

Click here to get full coverage on Arvinas and Pfizer Announce Out-Licensing Strategy for Vepdegestrant and Cost Optimization Initiatives - Quiver Quantitative

Arvinas and Pfizer Announce Out-Licensing Strategy for Vepdegestrant and Cost Optimization Initiatives  Quiver Quantitative

Arvinas and Pfizer Announce Out-Licensing Strategy for Vepdegestrant and Cost Optimization Initiatives - Quiver Quantitative

Click here to get full coverage on Arvinas to Present Phase 1 Data for ARV-102, a PROTAC LRRK2 - GlobeNewswire

Arvinas to Present Phase 1 Data for ARV-102, a PROTAC LRRK2  GlobeNewswire

Arvinas to Present Phase 1 Data for ARV-102, a PROTAC LRRK2 - GlobeNewswire

Click here to get full coverage on Arvinas (ARVN): Wells Fargo Lowers Price Target to $15 | ARVN St - GuruFocus

Arvinas (ARVN): Wells Fargo Lowers Price Target to $15 | ARVN St  GuruFocus

Arvinas (ARVN): Wells Fargo Lowers Price Target to $15 | ARVN St - GuruFocus

Click here to get full coverage on Arvinas: Approvable, But Asset Looks Mediocre, Initiating With A Hold Rating (NASDAQ:ARVN) - Seeking Alpha

Arvinas: Approvable, But Asset Looks Mediocre, Initiating With A Hold Rating (NASDAQ:ARVN)  Seeking Alpha

Arvinas: Approvable, But Asset Looks Mediocre, Initiating With A Hold Rating (NASDAQ:ARVN) - Seeking Alpha

Click here to get full coverage on Arvinas (ARVN) Q4 2025 Earnings Call Transcript - The Globe and Mail

Arvinas (ARVN) Q4 2025 Earnings Call Transcript  The Globe and Mail

Arvinas (ARVN) Q4 2025 Earnings Call Transcript - The Globe and Mail

Click here to get full coverage on Earnings Flash (ARVN) Arvinas, Inc. Reports Q4 Revenue $9.5M, vs. FactSet Est of $37.3M - marketscreener.com

Earnings Flash (ARVN) Arvinas, Inc. Reports Q4 Revenue $9.5M, vs. FactSet Est of $37.3M  marketscreener.com

ARVN

Price Chart

Key Statistics

Technicals

About ARVN

Latest News

Why (ARVN) Price Action Is Critical for Tactical Trading - Stock Traders Daily

Arvinas (ARVN) moves 6.9% higher: Will this strength last? - MSN

How The Arvinas (ARVN) Story Is Evolving As 2026 Neurology Catalysts Approach - Yahoo Finance

Advanced Charts

Top Gainers

Top Losers